Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXACT-2 trial of XC001 for refractory angina
NL-OMON59460Phase 2Suspended
- Sponsor
- XyloCor Therapeutics
- Start
- May 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of encoberminogene rezmadenovec in angina pectoris and coronary arteriosclerosis (2 arms), sponsored by XyloCor Therapeutics. Primary endpoint: Primary composite therapy response endpoint. Started May 2026; status: suspended.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON59460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59460.